RE:Lead Sponsor 15 Minutes of FameLooks like its not just Dr. Norman Wong giving a 15 minute talk tomorrow on RVX-208 representing Resverlogix, but following Dr. Wong is Kevin McLure from Zenith giving a 15 minute talk on BET inhibitors, oncology and autoimmune disease.
https://epic-boston.com/agenda/day-one
| 10.25 RVX-208 a BET inhibitor that raises ApoA-I in human clinical trials - RVX-208 is a selective BET inhibitor that induces ApoA-1 gene transcription.
- Preclinical data and data from human clinical trials are presented.
- Post hoc analysis from the latest clinical trials are discussed
| | Norman Wong, CSO,Resverlogix Corp |
..........................................................................................................................................................................................................
| 10.40 Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. - A robust discovery platform that has generated high potency BETi with desirable pharmaceutical properties.
- ZEN-3365 was selected for clinical development for hematologic cancers and solid tumors and shows excellent preclinical efficacy.
- In vivo proof of concept in multiple models of Autoimmune has been demonstrated.
| | Kevin G McLure, PhD, Senior Director of Translational Biology,Zenith Epigenetics Corp |